CRISPR Therapeutics AG (CRSP)

HEALTH CARE: BIOTECHNOLOGY & LIFE SCIENCES
SIC: BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES)

BAARERSTRASSE 14 ZUG, SWITZERLAND CH-6300

CRISPR Therapeutics AG is a bio-technology company. The Company researches, develops, and manufactures biological transformative gene-based medicines and other related products. CRISPR Therapeutics operates in Switzerland.

Data based on most recent fiscal year report
Market Cap1.956 Billion Shares Outstanding45.89 Million Avg Volume555.971 Thousand
1-Yr BETA vs S&P TR2.202 Current Ratio17.12 Quick Ratio17.12
View SEC Filings from CRSP instead.
Q2 2019 All Institutions Hedge Funds 1
To trade CRSP now:
Filers who had this stock in their top 10: 6 1 (0.1%)
13F Filers holding this stock: 171 24 (2.48%)
Aggregate 13F shares on 06/30/2019: 27.393 Million 4.857 Million
Aggregate 13F shares on 03/31/2019: 25.936 Million 5.524 Million
Percent change: 5.62% -12.08%
Funds creating new positions: 41 11
Funds Adding to an existing position: 43 3
Funds closing out their position: 29 4
Funds reducing their position: 35 8
1 hedge funds as identified by whalewisdom.com through public filings.

View recent insider trading info

Funds Holding CRSP (via 13F filings)

Refresh Download CSV Download Excel (.xlsx) Download TSV
Filter by:
to
to
to
Refresh
*Shares are split adjusted
*Please note that if a filer hasn't submitted a 13F filing for a quarter then the filer's shares will be listed as "Sold All"

Active Schedule 13D and 13G filings

Please sign in first

Open Market Buys/Sells Last 60 Days

Open Market Buys (P)

none

Open Market Sells (S)

28.5 Thousand total shares from 2 transactions

Exercise Derivative Conversion (M)

7.5 Thousand total shares from 1 transactions

Current/Former Insiders

Insider Name Type Last Reported Shares Held Last Reported Date Filings in past year

BOLZON BRADLEY J PHD

  • Director
4,247,615 2019-10-30 2

CAGNONI PABLO J

  • Director
0 2019-10-30 2

BEHBAHANI ALI

  • Director
0 2019-10-30 1

GLAXOSMITHKLINE PLC

  • 10% Owner
10,238,244 2019-10-29 0

GEORGE SIMEON

  • Director
2,982,855 2019-10-18 1

HADLEY HARBOR MASTER INVESTORS (CAYMAN) L.P.

  • 10% Owner
0 2019-09-30 0

GREENE JOHN EVP & CHIEF FINANCIAL OFFICER

1,066 2019-09-18 2

KASINGER JAMES R. GENERAL COUNSEL AND SECRETARY

  • Officer
0 2019-09-10 2

KLEIN LAWRENCE OTTO CHIEF BUSINESS OFFICER

  • Officer
0 2019-09-10 5

KULKARNI SAMARTH CHIEF EXECUTIVE OFFICER

  • Officer
  • Director
165,061 2019-09-01 8

HO TONY W EXECUTIVE VP, HEAD OF R&D

  • Officer
45,835 2019-08-01 2

WOIWODE THOMAS

  • Director
0 2019-07-31 0

COLES N ANTHONY

  • Director
1,296 2019-07-31 0

NOVAK RODGER PRESIDENT

  • Officer
  • Director
848,007 2019-07-10 5

HIGH KATHERINE A

  • Director
0 2019-06-11 2

TOMSICEK MICHAEL JOHN

  • Director
0 2019-05-08 1

EMSTER KURT VON

  • Director
0 2019-01-29 2

CELGENE CORP /DE/

6,824,685 2019-01-18 0

VERTEX PHARMACEUTICALS (EUROPE) LTD

VERTEX PHARMACEUTICALS INC / MA

  • 10% Owner
5,380,940 2018-12-26 2

BECKER MARC

  • Director
0 2018-06-25 0

VERSANT VENTURE CAPITAL V, L.P.

VERSANT VENTURES V, LLC

VERSANT AFFILIATES FUND V, L.P.

VERSANT OPHTHALMIC AFFILIATES I, L.P.

VERSANT VENTURE CAPITAL V (CANADA), LP

  • 10% Owner
1,729,151 2018-04-24 0

VERSANT VENTURE CAPITAL IV, L.P.

VERSANT SIDE FUND IV, L.P.

VERSANT VENTURES IV, LLC

VERSANT VENTURE CAPITAL V, L.P.

VERSANT AFFILIATES FUND V, L.P.

VERSANT OPHTHALMIC AFFILIATES I, L.P.

VERSANT VENTURE CAPITAL V (CANADA), LP

  • 10% Owner
4,004,248 2018-04-20 0

DYLAN-HYDE TYLER CHIEF LEGAL OFFICER

  • Officer
25,204 2018-01-16 0

BAYER AKTIENGESELLSCHAFT

BAYER GLOBAL INVESTMENTS B.V.

  • 10% Owner
5,708,747 2018-01-05 0

VERSANT VENTURE CAPITAL IV, L.P.

VERSANT SIDE FUND IV, L.P.

VERSANT VENTURE CAPITAL V, L.P.

VERSANT AFFILIATES FUND V, L.P.

VERSANT OPHTHALMIC AFFILIATES I, L.P.

VERSANT VENTURE CAPITAL V (CANADA), LP

VERSANT VENTURES IV, LLC

VERSANT VENTURES V, LLC

VERSANT VENTURES V (CANADA), L.P.

  • 10% Owner
4,606,242 2017-09-05 0

SUBRAMANIAN KALA SEE REMARKS

  • Officer
0 2017-06-15 0

LUNDBERG SVEN ANTE CHIEF SCIENTIFIC OFFICER

  • Officer
1,010,834 2016-10-24 0

VERSANT VENTURE CAPITAL IV, L.P.

VERSANT SIDE FUND IV, L.P.

VERSANT VENTURE CAPITAL V, L.P.

VERSANT AFFILIATES FUND V, L.P.

VERSANT OPHTHALMIC AFFILIATES I, L.P.

VERSANT VENTURE CAPITAL V (CANADA), LP

  • 10% Owner
6,909,347 2016-10-24 0

VERSANT VENTURE CAPITAL IV, L.P.

VERSANT SIDE FUND IV, L.P.

VERSANT VENTURE CAPITAL V, L.P.

VERSANT VENTURE CAPITAL V (CANADA), LP

  • 10% Owner
6,758,169 2016-10-24 0

Insider Transactions Last 60 Days

Reporting Owners Transaction Date Transaction Code Shares Share Price Acquired or Disposed Shares Owned Following Transaction Combined shares owned after filing Direct/Indirect Ownership 10b-5

BOLZON BRADLEY J PHD - Director

2019-10-30 S 21,000 $51.89 d 13,745 4,247,615.00 direct yes

CAGNONI PABLO J - Director

2019-10-30 S 7,500 $52.00 d 0 0.00 direct yes

CAGNONI PABLO J - Director

2019-10-30 M 7,500 $5.59 a 7,500 0.00 direct

CAGNONI PABLO J - Director

2019-10-30 M 7,500 d 78,833 0.00 direct
Click here to report any possible errors with this stock listing.

Elevate your investments